Skip to main content

Robust clinical data, supported by >10 years of real-world experience1 

 

References

1. ALPROLIX Package Insert. FDA. Revised May 2023. 2. ALPROLIX UK Summary of Product Characteristics. 3. ALPROLIX EU Summary of Product Characteristics. 

← physical function
DOSING →




ALPROLIX is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency). ALPROLIX can be used for all age groups.2,3

Adverse events should be reported. Reporting forms and information can be found, for United Kingdom: via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. For Ireland: via HPRA Pharmacovigilance website www.hpra.ie. Adverse events should also be reported to Swedish Orphan Biovitrum Ltd by email at [email protected] or by calling +44 (0) 800 111 4754.

 

PP-30698